{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06365619",
            "orgStudyIdInfo": {
                "id": "HCI168525"
            },
            "organization": {
                "fullName": "University of Utah",
                "class": "OTHER"
            },
            "briefTitle": "Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma",
            "officialTitle": "Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma",
            "acronym": "NeoRelapse",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "neoadjuvant-ipilimumab-nivolumab-for-patients-with-recurrent-high-risk-resectable-melanoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-09",
            "studyFirstSubmitQcDate": "2024-04-09",
            "studyFirstPostDateStruct": {
                "date": "2024-04-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Utah",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy.\n\nParticipants will receive 2 cycles of treatment prior to their standard of care surgery. After surgery participants will receive standard of care adjuvant therapy and be followed for response."
        },
        "conditionsModule": {
            "conditions": [
                "Melanoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 25,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment: All Patients",
                    "type": "EXPERIMENTAL",
                    "description": "Neoadjuvant Ipilimumab and Nivolumab",
                    "interventionNames": [
                        "Drug: Ipilimumab",
                        "Drug: Nivolumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ipilimumab",
                    "description": "Two cycles of neoadjuvant ipilimumab prior to surgical resection.",
                    "armGroupLabels": [
                        "Treatment: All Patients"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nivolumab",
                    "description": "two cycles of neoadjuvant nivolumab prior to surgical resection.",
                    "armGroupLabels": [
                        "Treatment: All Patients"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Rate of pathologic response rate (pCR, mCR/nCR, or pPR) at the time of surgery.",
                    "description": "Assess the pathologic response rate (pRR) at the time of surgery after two doses of neoadjuvant Ipilimumab and Nivolumab for patients that have recurred while receiving/recently completed adjuvant anti-PD1 therapy.",
                    "timeFrame": "2 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.",
                    "description": "Assess the safety and tolerability of Ipilimumab and Nivolumab in the study population.",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Rate of adverse events that occur within 30 days post-surgery.",
                    "description": "Assess the impact of neoadjuvant ipi/nivo on morbidity of definitive surgery.",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Rate of Event Free Survival (EFS).",
                    "description": "Assess EFS in the study population.",
                    "timeFrame": "11 years"
                },
                {
                    "measure": "Rate of Overall Survival (OS).",
                    "description": "Assess OS in this study population.",
                    "timeFrame": "11 years"
                },
                {
                    "measure": "Objective response rate (ORR) defined as the proportion of subjects achieving a confirmed PR and CR as defined by RECIST 1.1 prior to surgical resection.",
                    "description": "Determine RECIST 1.1 response rate (confirmed CR and PR) before surgical resection and to evaluate associations between radiographic and pathologic response rate and event free survival/overall survival.",
                    "timeFrame": "11 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects aged \u2265 18 years.\n* Histologically confirmed Stage IIIB-D or Stage IV recurrent metastatic melanoma that is resectable or borderline resectable as determined by a Surgical Oncologist.\n* Recurrent disease at eligibility must have been confirmed with biopsy while receiving or within 3 months of completion of adjuvant anti-PD1 therapy.\n* ECOG Performance Status \u2264 1.\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Absolute neutrophil count (ANC) \u2265 1500/mm3\n    * Platelet count \u2265 100,000/mm3\n    * Hemoglobin \u2265 10 g/dL\n  * Hepatic:\n\n    * Total Bilirubin \u2264 1.5x institutional upper limit of normal (ULN)\n    * AST(SGOT)/ALT(SGPT) \u2264 3 \u00d7 institutional ULN ----Subjects with liver metastases will be allowed to enroll with AST and ALT levels \u2264 5 x ULN.\n  * Renal:\n\n    * Estimated creatinine clearance \u2265 50 mL/min by Cockcroft-Gault formula:\n* For subjects of childbearing potential: Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Subjects \\< 50 years of age:\n\n    * Amenorrheic for \u2265 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n  * Subjects \u2265 50 years of age:\n\n    * Amenorrheic for \u2265 12 months following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago\n* Subjects of childbearing potential and subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.3.1.\n* Subject has adequate archival tissue or agrees to undergo a fresh tissue biopsy if sufficient archival tissue is unavailable.\n* Recovery to baseline or \u2264 Grade 1 CTCAE v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy per the treating investigator.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Receiving other investigational agents currently or within 28 days of study treatment.\n* Prior systemic anti-cancer therapy \u2264 14 days or within five half-lives prior to starting study treatment, whichever is shorter.\n* Prior radiotherapy 45 days prior to the first dose of study treatment.\n* Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery.\n* Active infection requiring the use of systemic antibiotics.\n* Systemic steroid therapy greater than physiologic equivalent (10mg prednisone/day) or any other form of systemic immunosuppressive therapy within 7 days prior to registration.\n* Active secondary malignancy, unless the malignancy is not expected to interfere with the evaluation of safety\n* Known brain metastases or cranial epidural disease.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n\n  --Cardiovascular disorders:\n  * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n  * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n  * QTc prolongation defined as a QTcF \\> 500 ms.\n  * Known congenital long QT.\n  * Left ventricular ejection fraction \\< 55%.\n  * Uncontrolled hypertension defined as \u2265 140/90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.\n* Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the drug through a feeding tube\\], social/psychological issues, etc.)\n* HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.\n\n  --Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (positive HBV surface antigen (HBsAg) result), or hepatitis C.\n\n  --Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v5.0 Grade \u2265 3).\n* Subjects taking prohibited medications as described in Section 6.7.2. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kaitlin Stephens",
                    "role": "CONTACT",
                    "phone": "801-213-8494",
                    "email": "kaitlin.stephens@hci.utah.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "John Hyngstrom, MD",
                    "affiliation": "Huntsman Cancer Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Huntsman Cancer Institute",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                },
                {
                    "id": "D000074324",
                    "term": "Ipilimumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1348",
                    "name": "Ipilimumab",
                    "asFound": "Enrolled",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}